Codiak BioSciences, Inc. Common Stock
CDAK
CDAK was delisted on the 4th of April, 2023.
62 hedge funds and large institutions have $86.5M invested in Codiak BioSciences, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 11 increasing their positions, 16 reducing their positions, and 5 closing their positions.
220% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 5
22% more funds holding
Funds holding: 51 → 62 (+11)
31% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 16
41% less capital invested
Capital invested by funds: $145M → $86.5M (-$58.9M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
100% less call options, than puts
Call options by funds: $1K | Put options by funds: $211K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$998K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$636K |
| 3 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$401K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$267K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$257K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$970K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$423K |
| 3 |
BlackRock
New York
|
-$91.8K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$89.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$41K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| $7K | -$22.6K | -3,596 | -75% |
|
52
Nisa Investment Advisors
St. Louis,
Missouri
| $7K | +$7.47K | +1,190 | New |
|
53
Royal Bank of Canada
Toronto,
Ontario, Canada
| $6K | -$16.4K | -2,605 | -73% |
|
54
US Bancorp
Minneapolis,
Minnesota
| $2K | – | – | – |
|
55
Simplex Trading
Chicago,
Illinois
| $1K | -$609 | -97 | -28% |
|
56
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $1K | – | – | – |
|
|
LWANC
57
Laurel Wealth Advisors (North Carolina)
Charlotte,
North Carolina
| $1K | – | – | – |
|
|
PFS
58
Prospera Financial Services
Dallas,
Texas
| $1K | +$559 | +89 | New |
|
|
59
UBS Group
Zurich,
Switzerland
| – | -$41K | -3,722 | Closed |
|
|
EVM
60
Eaton Vance Management
Boston,
Massachusetts
| – | -$22K | -2,000 | Closed |
|
|
MIFH
61
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
| – | -$4K | -341 | Closed |
|
62
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$2K | -200 | Closed |
|
|
TFA
63
Toth Financial Advisory
Leesburg,
Virginia
| – | -$1K | -100 | Closed |
|
64
Osaic Holdings
Scottsdale,
Arizona
| – | +$119 | +19 | +100% |
|
CDAK Hedge Fund Activity: Q1 2022 in Review
62 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Codiak BioSciences, Inc. Common Stock (CDAK) for Q1 2022, worth a combined $86.5M — down 41% from $145M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new CDAK positions and 5 closed out — a net gain of 11 holders — while 11 added to existing stakes and 16 trimmed.
The largest buyer was Ensign Peak Advisors, adding an estimated $998K. The largest seller was Oracle Investment Management, cutting an estimated $970K.
- 62 institutional investors held Codiak BioSciences, Inc. Common Stock (CDAK) as of Q1 2022, up from 51 in Q4 2021.
- Funds reported $86.5M of Codiak BioSciences, Inc. Common Stock stock for Q1 2022, down 41% quarter-over-quarter.
- 16 funds opened new Codiak BioSciences, Inc. Common Stock positions in Q1 2022 and 5 closed out, a net change of +11 holders.
- The largest Codiak BioSciences, Inc. Common Stock buyer in Q1 2022 was Ensign Peak Advisors, an estimated $998K added.
- The largest Codiak BioSciences, Inc. Common Stock seller in Q1 2022 was Oracle Investment Management, an estimated $970K sold.
Based on aggregated 13F filings for Q1 2022.